Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced its participation in the Canaccord Genuity Growth Conference. Nick Colangelo, the company's President and CEO, is scheduled to present on Wednesday, August 14, 2024, at 3:00 p.m. ET.
This presentation offers an opportunity for investors and interested parties to gain insights into Vericel's operations and growth strategies. The company has made the event accessible to a wider audience by providing a webcast of the presentation, which will be available on the Investor Relations section of Vericel's official website at http://investors.vcel.com.
Vericel's participation in this conference underscores its commitment to transparency and engagement with the investment community, potentially impacting its market position and investor relations.
Vericel (NASDAQ:VCEL), un leader nelle terapie avanzate per la medicina sportiva e la cura di gravi ustioni, ha annunciato la sua partecipazione alla Canaccord Genuity Growth Conference. Nick Colangelo, Presidente e CEO dell'azienda, è previsto per una presentazione mercoledì 14 agosto 2024, alle 15:00 ET.
Questa presentazione offre l'opportunità a investitori e parti interessate di ottenere approfondimenti sulle operazioni e le strategie di crescita di Vericel. L'azienda ha reso l'evento accessibile a un pubblico più ampio fornendo un webcast della presentazione, che sarà disponibile nella sezione Investor Relations del sito ufficiale di Vericel all'indirizzo http://investors.vcel.com.
La partecipazione di Vericel a questa conferenza sottolinea il suo impegno verso la trasparenza e il coinvolgimento con la comunità degli investitori, con potenziali ripercussioni sulla sua posizione di mercato e sulle relazioni con gli investitori.
Vericel (NASDAQ:VCEL), un líder en terapias avanzadas para la medicina deportiva y el tratamiento de quemaduras severas, ha anunciado su participación en la Canaccord Genuity Growth Conference. Nick Colangelo, presidente y CEO de la compañía, tiene programada una presentación el miércoles 14 de agosto de 2024, a las 3:00 p.m. ET.
Esta presentación ofrece una oportunidad para que inversionistas y partes interesadas obtengan información sobre las operaciones y estrategias de crecimiento de Vericel. La compañía ha hecho que el evento sea accesible a una audiencia más amplia al proporcionar un webcast de la presentación, que estará disponible en la sección de Relaciones con Inversores en el sitio web oficial de Vericel en http://investors.vcel.com.
La participación de Vericel en esta conferencia subraya su compromiso con la transparencia y el compromiso con la comunidad inversionista, lo que podría impactar su posición en el mercado y las relaciones con los inversores.
Vericel (NASDAQ:VCEL)은 스포츠 의학 및 중증 화상 치료를 위한 첨단 치료법의 선두주자로서 Canaccord Genuity Growth Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Nick Colangelo는 2024년 8월 14일 수요일 오후 3시(ET)에 발표할 예정입니다.
이번 발표는 투자자와 관심 있는 관계자들이 Vericel의 운영 및 성장 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다. 회사는 프레젠테이션 웹캐스트를 제공하여 더 넓은 청중이 이 행사에 접근할 수 있도록 하였으며, 이는 Vericel 공식 웹사이트의 투자자 관계 섹션인 http://investors.vcel.com에서 확인할 수 있습니다.
Vericel의 이번 컨퍼런스 참여는 투자자 커뮤니티와의 투명성과 참여 의지를 강조하며, 이는 시장에서의 위치와 투자자 관계에 잠재적인 영향을 미칠 수 있습니다.
Vericel (NASDAQ:VCEL), un leader dans les thérapies avancées pour la médecine du sport et les soins des brûlures sévères, a annoncé sa participation à la Canaccord Genuity Growth Conference. Nick Colangelo, le président et PDG de l'entreprise, doit faire une présentation le mercredi 14 août 2024, à 15h00 ET.
Cette présentation offre une opportunité aux investisseurs et aux parties intéressées d'obtenir des informations sur les opérations et les stratégies de croissance de Vericel. L'entreprise a rendu l'événement accessible à un public plus large en fournissant un webcast de la présentation, qui sera disponible dans la section Relations avec les investisseurs du site officiel de Vericel à l'adresse http://investors.vcel.com.
La participation de Vericel à cette conférence souligne son engagement en faveur de la transparence et de l'engagement avec la communauté des investisseurs, ce qui pourrait avoir un impact sur sa position sur le marché et ses relations avec les investisseurs.
Vericel (NASDAQ:VCEL), ein führendes Unternehmen für fortschrittliche Therapien in der Sportmedizin und der Behandlung schwerer Verbrennungen, hat seine Teilnahme an der Canaccord Genuity Growth Conference angekündigt. Nick Colangelo, der Präsident und CEO des Unternehmens, wird voraussichtlich am Mittwoch, dem 14. August 2024, um 15:00 Uhr ET präsentieren.
Diese Präsentation bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Geschäftstätigkeiten und Wachstumsstrategien von Vericel zu gewinnen. Das Unternehmen hat die Veranstaltung für ein breiteres Publikum zugänglich gemacht, indem es einen Webcast der Präsentation bereitstellt, der im Abschnitt Investor Relations auf der offiziellen Website von Vericel unter http://investors.vcel.com verfügbar sein wird.
Die Teilnahme von Vericel an dieser Konferenz unterstreicht dessen Engagement für Transparenz und den Umgang mit der Investoren-Community, was potenziell Auswirkungen auf die Marktposition und die Beziehungen zu den Investoren haben kann.
- None.
- None.
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Growth Conference at 3:00 p.m. ET on Wednesday, August 14, 2024.
A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
FAQ
When is Vericel (VCEL) presenting at the Canaccord Genuity Growth Conference?
Who will be presenting for Vericel (VCEL) at the Canaccord Genuity Growth Conference?
How can I watch Vericel's (VCEL) presentation at the Canaccord Genuity Growth Conference?
What markets does Vericel (VCEL) operate in?
